Publications

5674 Results

A meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer

Authors
S Halabi;W Kelly;H Ma;H Zhou;N Solomon;K Fizazi;C Tangen;M Rosenthal;D Petrylak;M Hussain;N Vogelzang;IM Thompson;KN Chi;J de Bono;A Armstrong;M Eisenberger;A Fandi;S Li;JC Araujo;C Logothetis;D Quinn;M Morris;C Higano;I Tannock;E Small
Journal / Conference
Journal of Clinical Oncology May 10;34(14):1652-1659
Year
2016
Research Committee(s)
Genitourinary
PMID
PMID26951312
PMC
PMC4872320
Study Number(s)
S0421, S9916

Biases in recommendations for and acceptance of prostate biopsy significantly affect assessment of prostate cancer risk factors. Results from two large randomized clinical trials

Authors
C Tangen;P Goodman;C Till;J Schenk Kisser;MS Lucia;IM Thompson
Journal / Conference
Journal of Clinical Oncology Dec 20;34(36):4338-4344. Epub 2016 Oct 28
Year
2016
Research Committee(s)
Cancer Control, Prevention, Screening, and and Surveillance
PMID
PMID27998216
PMC
PMC5455311
Study Number(s)
S0000, SWOG-9217

Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration resistant prostate cancer (mCRPC) treated on SWOG study S0421

Authors
G Pond;G Sonpavde;M Plets;C Tangen;M Hussain;P Lara;A Goldkorn;M Garzotto;C Higano;N Vogelzang;IM Thompson;P Twardowski;P Van Veldhuizen;N Agarwal;M Carducci;JP Monk;DI Quinn
Journal / Conference
Journal of Clinical Oncology 34, 2016 (suppl; abstr 5079) American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session
Year
2016
Research Committee(s)
Genitourinary
Study Number(s)
S0421

Outcomes for patients treated with or without bevacizumab on SWOG S0819: a randomized, phase III study comparing carboplatin/paclitaxel or carboplatin/paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC)

Authors
T Semrad;M Redman;R Herbst;ES Kim;L Bazhenova;G Masters;K Oettel;P Guaglianone;C Reynolds;A Karnad;S Arnold;M Varella Garcia;J Moon;P Mack;C Blanke;FR Hirsch;K Kelly;D Gandara
Journal / Conference
Journal of Clinical Oncology 34, 2016 (supp;abstr 9082);American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session
Year
2016
Research Committee(s)
Lung
Study Number(s)
S0819

SWOG S1206: A dose-finding study of veliparib (ABT-888) added to chemoradiotherapy (CRT) with carboplatin (C) and paclitaxel (P) for unresectable stage III non-small cell lung cancer (NSCLC)

Authors
M Cristea;J Miao;A Argiris;A Chen;M Daly;R Decker;L Garland;D Wang;M Koczywas;J Moon;K Kelly;D Gandara
Journal / Conference
Journal of Clinical Oncology 34, 2016 (suppl; abstr 8537); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session
Year
2016
Research Committee(s)
Lung
Study Number(s)
S1206 (8811)

Lung-MAP (S1400) Lung Cancer Master Protocol: Accrual, demographics, and molecular markers

Authors
V Papadimitrakopoulou;M Redman;D Gandara;F Hirsch;P Mack;H Gorghaei;C Langer;J Engelman;M Edelman;K Albain;P Lara;C Aggarwal;M Socinski;S Gettinger;L Bazhenova;S Malik;S McDonough;E Sigal;K Kelly;R Herbst
Journal / Conference
J Clin Oncol 36, 2018 (suppl; abstr 9019); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session
Year
2016
Research Committee(s)
Lung
Study Number(s)
S1400

Circulating tumor cells (CTCs) in SWOG S1216: a phase 3 multicenter trial in metastatic hormone sensitive prostate cancer (mHSPC)

Authors
A Goldkorn;M Plets;N Agarwal;M Hussain;P Lara;D Vaena;G MacVicar;T Crispino;A Harzstark;P Twardowski;C Tangen;C Hugen;T Xu;Y Xu;J Pinski;S Ingles;C Higano;N Vogelzang;I Thompson;D Quinn
Journal / Conference
Journal of Clinical Oncology 34, 2016 (suppl; abstr 11516); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster discussion
Year
2016
Research Committee(s)
Genitourinary
Study Number(s)
S1216

SWOG S1404: A phase III randomized trial comparing high dose interferon to pembrolizumab in patients with high risk resected melanoma

Authors
K Grossman;M Othus;A Tarhini;SP Patel;J Moon;V Sondak;JM Kirkwood;A Ribas
Journal / Conference
Journal of Clinical Oncology 34, 2016 (suppl; abstr e21032); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), publication only
Year
2016
Research Committee(s)
Melanoma
Study Number(s)
S1404

SWOG S1505: A randomized phase II study of perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as therapy for resectable pancreatic adenocarcinoma

Authors
D Sohal;K Guthrie;S Ahmad;N Gandhi;M Shaalan Beg;A Wang Gillam;S McDonough;A Lowy;P Philip;H Hochster
Journal / Conference
Journal of Clinical Oncology 34, 2016 (suppl; abstr TPS4151); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL) TIP, poster session
Year
2016
Research Committee(s)
Gastrointestinal
Study Number(s)
S1505

Randomized trial of medroxyprogesterone acetate for prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630 (ClinicalTrials.gov NCT00002920)

Authors
K Albain;J Unger;R Livingston;K Crew;S Wilczynski;C Salomon;BL Smith;L Wong;DL Campbell;D Einspahr;G Anderson;D Hershman;G Goodman;PH Brown;F Meyskens;R Potkul
Journal / Conference
Journal of Clinical Oncology 34, 2016 (suppl; abstr 547); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session
Year
2016
Research Committee(s)
Breast
Study Number(s)
S9630